PCVX (SutroVax) Earnings per share growth rate in current year

The rise in Vaxcyte, Inc. (PCVX) share prices is driven by the development of innovative vaccines and significant research capital. The annual earnings per share growth profile in the daily price action on the GURU.Markets chart recorded a value of -39.10. This is supported by the expertise of US laboratories in combating infections and the seamless operation of certified plants producing experimental drugs.

vaxcyte.com (PCVX): Net earnings per share growth this year from 07/04/2022 to 11/14/2026

Analytical breakdowns and data insights for company Vaxcyte, Inc. (PCVX)

- current price and projected stock value:

Quote Chart Vaxcyte Inc|PCVX - Analyst Consensus Forecast

- business market valuation indicators:

Market Value SutroVax|PCVX - Enterprise Value

- balance sheet equity data:

Accounting Value per Share Vaxcyte|PCVX - Company Net Assets|Market Cap to Book Value Multiple vaxcyte.com|PCVX - Company Total Assets

- debt burden and liquidity indicators:

- net income and valuation ratios data:

PCVX - Net Profit|Projected Future Earnings Vaxcyte, Inc.|PCVX - Price to Earnings Ratio|Price to Future Earnings Ratio SutroVax|PCVX - PEG Multiple|Enterprise Value to EBITDA Ratio SutroVax|PCVX - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Vaxcyte|PCVX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months vaxcyte.com|PCVX - Earnings growth in current year|Expected net earnings per share growth next year Vaxcyte, Inc.

- company sales and revenue statistics:

PCVX - Company Sales|Company Future Revenue Vaxcyte Inc|PCVX - P/S Multiple|Market Cap to Expected Sales Ratio SutroVax

Basic company analysis:Vaxcyte Inc

Vaxcyte, Inc. (PCVX) leverages its innovative cell-free platform for creating ultra-broad vaccines to drive long-term business value, a trend reflected in the year-over-year EPS growth. This indicator measures the percentage change in net income per share compared to the same period last year, allowing investors to assess how effectively the company capitalizes on its technological advantage amidst market volatility.

Main competitors